GlassScriptPhysician profile
Vincent M Deninis
NPI 1730660846
$1,443.37
in general payments reported to CMS, 2019-2025
15 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $298 · 2021: $163 · 2022: $335 · 2023: $342 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $449.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $510.54 | 2020-2025 | Cequa |
| Eyevance Pharmaceuticals LLC | $160.57 | 2021-2022 | |
| Genzyme Corporation | $117.68 | 2019 | |
| Allergan, INC. | $109.94 | 2020 | |
| Genentech USA, INC. | $109.65 | 2023 | Vabysmo |
| Sight Sciences, INC. | $107.77 | 2020 | |
| Biotissue Holdings INC. | $80.35 | 2019 | |
| Bausch & Lomb Americas INC. | $77.29 | 2022-2025 | Miebo, Infuse |
| Aerie Pharmaceuticals, INC. | $41.58 | 2021 | |
| Alcon Vision LLC | $35.76 | 2021 | |
| Coopervision INC. | $21.19 | 2021 | |
| Astellas Pharma US INC | $20.68 | 2025 | Izervay |
| Dompe US, INC. | $18.99 | 2025 | Oxervate |
| Oyster Point Pharma, INC. | $16.05 | 2022 | |
| Apellis Pharmaceuticals, INC. | $15.33 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Deninis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.